Search

Artificial intelligence is rapidly entering pharmaceutical manufacturing through predictive analytics, process analytical technology, continuous manufacturing platforms, and data-driven quality control. These developments promise earlier detection of process deviation, adaptive optimization of critical process parameters, and more responsive assurance of critical quality attributes. Yet the dominant regulatory and quality vocabulary remains anchored in Quality-by-Design, a paradigm built around pre-defined knowledge, structured risk assessment, and validated control strategies. The central problem is that AI-assisted manufacturing systems do not behave like conventional pharmaceutical processes governed solely through fixed design spaces. Machine learning models may change performance as data distributions shift, as sensors age, as materials vary, or as feedback loops alter the operating environment. This creates a governance gap between the static logic of pre-validation and the dynamic reality of algorithmic decision-making. This critical conceptual review examines whether Quality-by-Design remains sufficient for AI-assisted pharmaceutical manufacturing. It argues that QbD is still necessary but no longer sufficient because it was designed for processes whose boundaries, models, and control logic can be defined before routine operation. AI-assisted systems require an additional governance logic capable of supervising data, models, explanations, adaptation, and accountability throughout the product lifecycle. The review develops the concept of Quality-by-Intelligence as a forward-looking governance framework. QbI does not discard QbD; rather, it extends it by embedding data stewardship, model lifecycle management, explainable decision-making, adaptive risk control, and regulatory translation into the pharmaceutical quality system. Its purpose is to govern not only the manufacturing process, but also the intelligence layer that increasingly mediates quality decisions. Quality-by-Intelligence reframes pharmaceutical quality as an adaptive, evidence-generating, and accountable system rather than a one-time design achievement. The transition will require new regulatory expectations, new validation evidence, new operator competencies, and stronger collaboration between industry, regulators, and academic experts. Without this shift, AI may be deployed into manufacturing faster than the quality systems needed to govern it.

Digital twins promise to reshape pharmaceutical development and manufacturing by creating virtual replicas that mirror physical systems over time. Their value lies in linking process knowledge, real-time data, predictive modelling, and decision support into a single operational framework. In pharmaceutical contexts, this promise is especially relevant because product quality is tightly coupled to process history, material attributes, and patient-facing performance. The core problem is that digital twin development in pharma remains fragmented across manufacturing, drug delivery, regulatory modelling, and digital transformation literatures. Manufacturing studies often focus on process control, PAT, and continuous production, whereas drug delivery studies emphasise physiological prediction, formulation performance, and patient-specific behaviour. These areas share mechanistic foundations, but they are rarely treated as parts of a unified pharmaceutical digital twin ecosystem. This conceptual review analyses digital twin logic across pharmaceutical manufacturing and drug delivery systems. It focuses on how mechanistic models, hybrid modelling, and real-time data infrastructures can be combined to support quality, performance prediction, and regulatory decision-making. The central argument is that digital twins must become not only predictive but also explainable and governable. The synthesis defines the architecture of pharmaceutical digital twins, catalogues their manufacturing and drug delivery applications, and identifies unresolved challenges in model coupling, parameter identifiability, uncertainty handling, and regulatory credibility. It also maps technological, organisational, economic, and regulatory barriers that prevent promising models from becoming routine industrial tools. Five tables summarise the conceptual architecture, application domains, model architectures, integration problems, and implementation barriers. Realising the full potential of pharmaceutical digital twins will require mechanistic rigour, explainable analytics, high-quality data connectivity, and early alignment with regulatory expectations. The future of the field will depend less on isolated demonstrations and more on reusable validation strategies, transparent model governance, and cross-sector collaboration. Digital twins should therefore be understood as evolving regulatory-scientific infrastructures rather than as standalone computational artefacts.

Continuous manufacturing has been promoted as a transformative alternative to batch pharmaceutical production because it can reduce equipment footprint, shorten development-to-commercialisation timelines, and enable more responsive quality assurance. Its appeal rests on the idea that material flows through an integrated process rather than waiting in isolated unit operations. Yet the technical maturity required to make that flow reliable is often understated. The central problem is that continuous operation is sometimes treated as intrinsically superior to batch production, as though continuity alone guarantees better quality. In practice, quality depends on the ability of sensors, models, actuators, supervisory logic, and operators to detect and correct deviations fast enough to prevent poor material from propagating through the line. Without that control capability, continuous systems may amplify rather than resolve process vulnerability. This critical review examines continuous pharmaceutical manufacturing through three linked lenses: control architecture design, process robustness, and regulatory translation. It asks whether current systems are sufficiently controlled to justify claims of superior quality, whether robustness is assessed with appropriate metrics, and whether regulatory frameworks have matured enough to support dynamic manufacturing strategies. The review deliberately treats continuous manufacturing as a socio-technical system rather than as a purely technological upgrade. The evidence indicates that continuous manufacturing has advanced substantially, particularly in direct compression, wet granulation, process analytical technology, residence-time modelling, soft sensing, and model predictive control. However, many demonstrations remain limited by narrow disturbance scenarios, incomplete treatment of start-up and shutdown, uncertain model maintenance requirements, and uneven translation into routine good manufacturing practice. Regulatory acceptance is progressing, but unresolved questions remain around batch definition, traceability, adaptive control validation, and lifecycle change management. The review concludes that continuous manufacturing is not an automatic guarantor of pharmaceutical quality. Its value depends on control-centric process design, standardised robustness assessment, credible digital and analytical infrastructure, and regulatory alignment that recognises dynamic process operation. The future pathway requires stronger pre-competitive collaboration, more realistic stress testing, and regulatory science that keeps pace with advanced control strategies.

Pharmaceutical 3D printing has emerged as a technically powerful approach for producing personalised, flexible, and on-demand dosage forms. Its appeal lies in the ability to vary dose, geometry, release profile, and patient acceptability without requiring a new conventional manufacturing line for every product variant. Despite this promise, the field remains constrained by a persistent mismatch between design capability and translational readiness. Many studies demonstrate sophisticated printed tablets, films, lattices, and personalised dosage forms, yet far fewer address the manufacturing controls, release strategies, and regulatory evidence needed for routine clinical implementation. This critical review evaluates pharmaceutical 3D printing through the connected lenses of design logic, manufacturing constraints, and regulatory readiness. The review treats additive manufacturing not as one technology but as a family of processes whose material requirements, process risks, and quality attributes differ substantially. The review concludes that pharmaceutical 3D printing will not translate through formulation novelty alone. A technology-agnostic, risk-proportionate regulatory pathway combined with scalable, PAT-integrated manufacturing platforms is essential to move from promise to practice.

Nanomedicines promise therapeutic advantages that are difficult to achieve with conventional dosage forms, including improved targeting, altered pharmacokinetics, protected delivery of fragile payloads, and platform adaptability across drug classes. Yet these benefits depend on manufacturing systems that can repeatedly generate nanoscale products within narrow physicochemical and biological performance windows. The central difficulty is that small changes in process conditions can produce disproportionate changes in particle size, morphology, surface properties, encapsulation efficiency, release behaviour, and biological interaction. Despite decades of academic activity, the translation of nanomedicine from laboratory prototypes to routine clinical and industrial products remains limited. Many formulations are optimised in small batches under conditions that are poorly suited to pilot or commercial production. As a result, promising nanocarriers may fail not because their therapeutic concept is weak, but because their quality attributes cannot be reproduced reliably at scale. The analysis identifies a systemic mismatch between laboratory-optimised formulation methods and industrial requirements for control, documentation, comparability, continuous monitoring, and GMP-ready reproducibility. Four tables synthesise manufacturing platforms, scale-up fragility points, reproducibility challenges, and regulatory or industrial barriers. Together, these syntheses support a translational quality framework centred on process understanding, platform logic, critical quality attributes, and regulatory co-evolution. The review concludes that nanomedicine translation cannot rely on linear scale-up assumptions. Robust translation requires a shift toward platform-based manufacturing, quality-by-design development, integrated process analytical technology, orthogonal characterisation, predictive scale-down models, and shared regulatory learning. Nanomedicines will become clinically credible only when therapeutic innovation is matched by reproducible, affordable, and auditable manufacturing systems.

Continuous pharmaceutical manufacturing has matured from a technical alternative to batch production into a strategically important manufacturing paradigm. Its promise lies in integrated material flow, smaller production footprints, improved process understanding, flexible scale-out, and the possibility of real-time quality assurance. Yet the quality systems used to govern continuous manufacturing often remain conceptually anchored in batch-era assumptions. The central problem addressed in this article is the mismatch between continuous manufacturing’s dynamic data environment and the inherited quality logic of discrete batch testing, fixed specifications, and retrospective release decisions. In batch quality logic, quality is often treated as a property confirmed after production. In continuous manufacturing, however, quality must be interpreted, predicted, and controlled while the process is still unfolding. This article proposes Lifecycle Intelligence as a theory-driven model for rethinking quality in continuous pharmaceutical manufacturing systems. Lifecycle Intelligence is defined as a quality paradigm in which process data, predictive models, control strategies, and lifecycle learning mechanisms are integrated to maintain quality dynamically across development, validation, commercial production, and post-approval improvement. The model shifts attention from isolated product release to continuous quality cognition. The argument advanced is that continuous manufacturing cannot reach its full quality and regulatory potential if it is governed primarily by batch quality logic. A lifecycle intelligence paradigm is needed to convert continuous data streams into validated quality decisions. This shift will require not only technical advances, but also new validation practices, model governance structures, regulatory dialogue, and workforce capabilities.

Most pharmaceutical manufacturing technologies are conceived in environments where electricity, purified water, skilled operators, calibrated instruments, and validated supply chains are treated as stable background conditions. These assumptions shape equipment selection, process control, formulation strategy, packaging design, and quality assurance architecture. When such technologies are transferred unchanged into low-resource environments, the hidden dependence on high-resource infrastructure becomes visible. The central problem is not simply scarcity but design-context mismatch. Technologies that require continuous utilities, specialist maintenance, narrow environmental control, or complex analytical confirmation may produce avoidable quality deviations, production interruptions, and inequitable access. Low-resource manufacturing therefore requires a design logic that begins with constraints rather than adapting to them after failure. The proposed approach translates infrastructure, workforce, supply-chain, and quality-system constraints into design requirements. It argues for simple, robust, modular, maintainable, and environmentally tolerant technologies that preserve critical quality attributes without requiring fragile operating conditions. Three tables support the framework by cataloguing constraints, technology principles, and decision logic. Frugal pharmaceutical design is not a lowering of standards. It is a disciplined method for building quality into technologies that must function where conventional manufacturing assumptions do not hold. Its wider adoption requires pharmaceutical scientists, regulators, global health practitioners, and local manufacturers to treat low-resource design as a legitimate and necessary branch of pharmaceutical technology.

The clinical success of mRNA–lipid nanoparticle vaccines transformed lipid nanoparticle technology from a specialised drug delivery field into a central modality for modern biopharmaceutical development. That success demonstrated that nucleic acid therapeutics can be manufactured, distributed, and deployed at unprecedented speed when formulation science, process engineering, and regulatory urgency align. Yet the same success also exposed how dependent LNP products remain on tightly constrained composition, process history, and cold-chain stability. The central problem is that processes optimised rapidly under pandemic conditions do not automatically constitute robust manufacturing platforms. Many LNP processes remain product-specific, empirically tuned, and sensitive to changes in lipid composition, aqueous phase conditions, mixing geometry, and downstream handling. The language of “platform” is therefore often stronger than the underlying evidence for generalisable process robustness. The review maps the structural and functional logic of LNP platforms, evaluates how mRNA delivery requirements shaped formulation choices, and assesses preclinical and manufacturing evidence across laboratory, preclinical, and scalable production contexts. It identifies recurrent fragility points including mixing sensitivity, particle heterogeneity, aggregation, mRNA degradation, storage instability, and incomplete comparability evidence after process change. Five tables summarise platform design, mRNA delivery requirements, manufacturing evidence, fragility points, and a system design strategy for robust LNP production. The post-mRNA era requires a shift from emergency product development to platform-centred system design. LNP manufacturing must become modular, measurable, scalable, and quality-resilient rather than merely reproducible under narrowly defined conditions. Achieving this transition is essential if LNP technologies are to move beyond COVID-19 vaccines into broader therapeutic applications and more equitable global health deployment.

The pharmaceutical industry is a significant contributor to environmental pollution, yet the sustainability of pharmaceutical technologies themselves has received less sustained attention than clinical efficacy, quality assurance, manufacturability, and cost. Pharmaceutical products are commonly evaluated through therapeutic performance and regulatory compliance, while the material, energy, solvent, water, packaging, and waste implications of their production and disposal remain secondary. This imbalance is no longer defensible as medicines become embedded within wider debates on planetary health, industrial decarbonisation, chemical pollution, and responsible innovation. Current pharmaceutical technology paradigms often depend on linear manufacturing models in which raw materials, solvents, excipients, packaging components, and delivery devices move through production and use before entering waste streams. This model is particularly problematic where complex formulations, multi-material packaging, single-use components, and persistent active substances create environmental burdens that are difficult to recover or neutralise. The problem is not only the presence of pharmaceuticals in the environment, but also the technological logic that normalises excess material throughput as an acceptable cost of product performance. This critical review examines sustainable pharmaceutical technologies through three connected lenses: green manufacturing, excipient burden, and circular design principles. Green manufacturing addresses how pharmaceutical products are synthesised, processed, purified, and scaled. Excipient burden focuses on the hidden environmental and functional load created by supposedly inactive formulation ingredients. Circular design principles extend the discussion beyond production efficiency toward products, packaging, and delivery systems designed for reduction, recovery, reuse, and responsible end-of-life management. The review identifies that continuous manufacturing, flow chemistry, process intensification, biocatalysis, solvent reduction, process mass intensity, and life-cycle assessment provide important but incomplete routes toward greener pharmaceutical production. It also shows that excipients, packaging, and drug delivery systems remain under-theorised in sustainability debates despite their cumulative contribution to material intensity, environmental persistence, and disposal complexity. Five tables present green manufacturing technologies, excipient burden data, circular design principles, environmental risks, and implementation barriers. The central conclusion is that sustainable pharmaceutical technology requires a systems-level transition rather than a collection of isolated green substitutions. Genuine sustainability will depend on integrating green manufacturing with excipient stewardship, circular product design, environmental risk reduction, regulatory adaptation, and cross-sector accountability. The field must therefore move from sustainability as a supplementary efficiency concern toward sustainability as a core design principle of pharmaceutical innovation.

The pharmaceutical industry is entering a period of accelerated digital transformation, driven by real-time sensing, automation, digital twins, advanced analytics, and connected healthcare technologies. Yet this transformation remains uneven across the pharmaceutical value chain. Manufacturing systems, quality systems, distribution infrastructures, and patient-facing technologies often evolve as separate digital domains rather than as components of one connected cyber-physical enterprise. This fragmentation limits the capacity of pharmaceutical organizations to use data as a continuous operational resource. A manufacturing line may generate rich process data, a quality system may generate release decisions, a distribution network may generate environmental and traceability records, and a connected device may generate adherence or use data, but these signals are rarely integrated into a unified architecture. As a result, the industry remains only partially able to close the loop between product design, production, delivery, use, and real-world performance. The objective of this article is to propose an integrated cyber-physical system architecture that links pharmaceutical manufacturing, quality control, distribution, and patient use into a coherent technical framework. The proposed architecture treats the pharmaceutical product not only as a manufactured physical object but also as a data-linked therapeutic system. In this view, quality, traceability, and patient performance are co-produced through connected material, digital, and process flows. The article develops a systems-architecture perspective rather than an empirical study. It synthesises peer-reviewed literature on Pharma 4.0, continuous manufacturing, process analytical technology, digital twins, real-time release, blockchain traceability, cold-chain monitoring, smart packaging, connected drug delivery devices, and digital adherence monitoring. These domains are integrated into a four-layer architecture that connects factory operations to patient-facing use environments. The proposed framework defines four architectural layers: manufacturing, quality control, distribution, and patient use. It then specifies the data, material, and process flows required to connect these layers into a continuous cyber-physical loop. Five tables are used to clarify the architecture problem, the manufacturing layer, the patient-use layer, the end-to-end flows, and the proposed integrated architecture. A pharmaceutical cyber-physical system spanning from raw material to patient outcome represents a potential next frontier in drug product quality, supply chain resilience, and personalised therapy. Such a system would require coordinated action across manufacturers, technology providers, healthcare systems, regulators, and patients. Its value lies not only in automation, but in the creation of a connected pharmaceutical enterprise capable of learning from every stage of the product lifecycle.

Pharmaceutical manufacturing is moving from automated equipment and digitally assisted control toward more autonomous systems capable of interpreting process data, adjusting operating conditions, and supporting quality decisions. This trajectory promises faster response, improved consistency, and more adaptive control across complex production environments. Yet autonomy also changes the nature of manufacturing responsibility because technical decisions increasingly occur inside algorithmic systems rather than through visible human judgement alone. The central problem addressed in this article is the trust deficit created by autonomous pharmaceutical manufacturing. When an algorithm modifies a critical process parameter, detects an anomaly, recommends batch continuation, or contributes to a quality disposition, regulators, operators, quality units, and patients require confidence that the decision remains safe, explainable, reversible, and accountable. Trust cannot be assumed simply because the system performs well during validation; it must be sustained over time as processes, materials, sensors, models, and organisational practices evolve. This article develops an original theory-driven framework for trustworthy autonomous pharmaceutical manufacturing. The framework is structured around three interdependent pillars: human oversight, model drift management, and quality accountability. These pillars are treated not as separate compliance add-ons but as mutually reinforcing design requirements for autonomous manufacturing systems operating in Good Manufacturing Practice environments. The article draws on a theoretical synthesis of peer-reviewed literature on pharmaceutical manufacturing automation, process analytical technology, machine learning, trust in automation, human–autonomy teaming, resilience engineering, socio-technical systems, and model drift. It reframes autonomous manufacturing as a socio-technical trust problem rather than a purely technical optimisation problem. Four tables map the theoretical foundations, oversight architectures, drift-management logic, and integrated Trustworthy System Framework. The proposed framework argues that trustworthiness in autonomous pharmaceutical manufacturing is not a property of an algorithm alone. It emerges from the designed relationship among people, models, process controls, quality systems, audit trails, and governance responsibilities. Autonomous manufacturing will become viable only when the system can remain technically reliable, humanly overseen, and institutionally accountable throughout its lifecycle.

Pharmaceutical quality is often operationalized through stability testing, in which products are exposed to defined temperature and humidity conditions to support shelf-life assignment. This practice is indispensable, but it can create a narrow interpretation of quality when stability under controlled chamber conditions is treated as evidence of real-world performance. Products do not move through idealized chambers; they move through development uncertainty, manufacturing variability, distribution stress, and patient-level handling. This article argues that the dominant stability paradigm has encouraged a conceptual conflation between stability and robustness. Stability testing primarily asks whether a product remains within specification under predefined storage conditions for a defined period. Robustness, by contrast, asks whether the product–process–use system can continue to deliver acceptable quality when exposed to interacting stresses across the full lifecycle. The objective of this article is to develop an Integrated Robustness Theory for pharmaceutical products. The theory frames robustness as a system-level property spanning development, manufacturing, storage, and administration. It proposes that quality should be understood not only as shelf-life survival but also as resilient performance under realistic and combined stress conditions. The article critiques the limits of stability testing, defines robustness dimensions across lifecycle phases, and develops a systems-based framework for translating robustness into development strategy, manufacturing control, storage evaluation, and administration design. Three tables are used to map lifecycle robustness dimensions, storage stress gaps, and the integrated theory. The central conclusion is that pharmaceutical quality assurance must move beyond shelf-life thinking toward lifecycle robustness thinking.

Digital batch records have commonly been implemented as electronic substitutes for paper documentation, preserving the logic of retrospective compliance rather than transforming the logic of pharmaceutical knowledge. This narrow implementation view treats the batch record as a repository of completed events, signatures, deviations, and release evidence. Such a view is increasingly insufficient for manufacturing environments shaped by automation, continuous processing, process analytical technology, and real-time quality expectations. This article reconceptualises digital batch records as pharmaceutical knowledge systems rather than electronic documentation artefacts. The central argument is that a digital batch record should not merely record what occurred during manufacturing, but should structure why it occurred, how it relates to process understanding, and how it informs quality decisions. This reframing is especially important for continuous manufacturing, where batch boundaries, material histories, and quality evidence are dynamic rather than fixed. The objective of the article is to develop a conceptual systems perspective on digital batch records for continuous manufacturing and regulatory inspection. The article synthesises peer-reviewed literature on pharmaceutical digitalisation, continuous manufacturing, data integrity, knowledge management, process control, real-time release testing, and regulatory science. It does not present new empirical data, but constructs a conceptual model from existing evidence and emerging regulatory trends. The article defines the system boundary of digital batch records, explains their knowledge logic, connects them to pharmaceutical knowledge management, and positions them as infrastructure for continuous manufacturing and inspection transformation. It argues that digital batch records can integrate process data, material traceability, critical quality attributes, audit trails, deviation logic, and lifecycle knowledge into a structured manufacturing intelligence layer. Four tables are used to clarify the proposed record logic, continuous manufacturing integration, inspection transformation, and knowledge-system architecture. The article concludes that digital batch records should be designed as the cognitive infrastructure of pharmaceutical quality. When architected as knowledge systems, they can support real-time quality assurance, predictive process oversight, continuous improvement, and more transparent regulatory interaction. The shift from record-keeping to knowledge-driven assurance is therefore not a technical upgrade alone, but a transformation in how pharmaceutical manufacturing knows, governs, and demonstrates quality.